NEWARK, CA / ACCESSWIRE / September 3, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in a fireside chat and one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY.
H.C. Wainwright 26th Annual Global Investment Conference - September 9-11, 2024
Format: Fireside Chat
Day/Time: Tuesday, September 10 at 1:30 P.M. ET
Webcast:
If you are interested in meeting with the Protagonist team during the conference, please reach out to your H.C. Wainwright representative.
About Protagonist
Protagonist Therapeutics is a biopharmaceutical company with peptide-based new chemical entities (NCEs) rusfertide and JNJ-2113 (formerly PN-235) in advanced Phase 3 stages of clinical development, both derived from the Company's proprietary technology platform. Protagonist and Johnson & Johnson (JNJ) scientists jointly discovered JNJ-2113 as part of Protagonist's Interleukin-23 receptor (IL-23R) antagonist collaboration with JNJ and followed it through IND-enabling pre-clinical and Phase 1 studies, with JNJ assuming responsibility for further clinical development. JNJ-2113 is currently being pursued in five Phase 3 studies in psoriasis, and a Phase 2b study in ulcerative colitis. Rusfertide, a mimetic of the natural hormone hepcidin, is the Company's lead drug candidate currently in a global Phase 3 development program for polycythemia vera (PV). The randomized portion of the Phase 2 REVIVE study has been successfully completed, and results were published in The New England Journal of Medicine in February 2024. The open-label extension (OLE) component of REVIVE has also been completed and is followed by an additional 2-year long-term extension (LTE) THRIVE study. Enrollment has been completed in the global Phase 3 VERIFY study of rusfertide in polycythemia vera. Rusfertide is being co-developed and co-commercialized with Takeda pursuant to a worldwide collaboration and license agreement with Takeda announced in January 2024.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at .
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Contact
Virginia Amann, Founder/CEO
ENTENTE Network of Companies
virginiaamann@ententeinc.com
SOURCE: Protagonist Therapeutics, Inc.